Friday - November 20, 2026
GE HealthCare's Phase 2 results support advancement of investigational manganese-based MRI contrast agent mangaciclanol into Phase 3 of LUMINA clinical trial
November 19, 2026
CHICAGO, Illinois, Nov. 19 [Category: Health Care] -- G.E. HealthCare posted the following news release:

* * *

GE HealthCare's Phase 2 results support advancement of investigational manganese-based MRI contrast agent mangaciclanol into Phase 3 of LUMINA clinical trial

*

Don't have an account?

CHALFONT ST GILES, UK -- 19 November, 2026 -- GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products